Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Ionized Calcium and Bleeding in Cardiac Surgery

3. června 2026 aktualizováno: Eero Pesonen, Helsinki University Central Hospital

Plasma Ionized Calcium and Perioperative Bleeding in Cardiac Surgery.

This retrospective study investigates the association between perioperative plasma ionized calcium concentration and perioperative bleeding in open-heart surgery. Excluding patients who meet exclusion criteria, the study will include all applicable adult patients who underwent cardiac surgery at Helsinki University Hospital between January 2021 and March 2026. As clinical routine, during both cardiac surgery and the subsequent intensive care period, multiple blood gas analyses were performed, including measurements of plasma ionized calcium concentration. Time-weighted averages of all measurements will be calculated across different phases of surgery (pre-CPB, on -CPB, post-CPB) and the first 24 hours of ICU stay (0-6 h, 6-12 h, 12-24 h). Perioperative bleeding will be assessed using the Universal Definition of Perioperative Bleeding (UDPB) classification validated for cardiac surgery. In addition to chest drain output, this classification accounts for blood products administered to treat bleeding (red blood cells, platelets, and fresh frozen plasma), pharmacological coagulation factor concentrates (fibrinogen/cryoprecipitate, PCC, aFVIIa) and surgical interventions (open sternum, resternotomy). The association between plasma ionized calcium and UDPB class will be assessed with regression models. The primary analysis will be the association between time-weighted mean plasma ionized calcium level during the post-CPB phase as a continuous variable and dichotomous UDPB (UDPB 3-4 vs. UDPB 0-2) in patients who did not receive blood products during the post-CPB phase. One secondary and two sensitivity analyses will be performed

Přehled studie

Postavení

Zatím nenabíráme

Detailní popis

PERIOPERATIVE TIME STAMPS: The perioperative phase is divided into the following time periods: the operating room phase before cardiopulmonary bypass (pre-CPB), cardiopulmonary bypass (on-CPB), the operating room phase after cardiopulmonary bypass (post-CPB), 0-6 hours in the intensive care unit (ICU-0-6h), 6-12 hours in the intensive care unit (ICU-6-12h), and 12-24 hours in the intensive care unit (ICU-12-24h). If the patient is transferred from the intensive care unit to the ward earlier than 24 hours after surgery, the final time period ends at the time of transfer.

PRIMARY ANALYSIS: The association between time-weighted mean plasma ionized calcium concentration during the post-CPB phase as a continuous variable and dichotomous UDPB (UDPB 3-4 vs. UDPB 0-2) in patients who did not receive blood products during the post-CPB phase. SECONDARY ANALYSIS: The association between time-weighted mean plasma ionized calcium concentration during the post-CPB phase as a continuous variable and the original five-grade UDPB in patients who did not receive blood products during the post-CPB phase. SENSITIVITY ANALYSES: The corresponding analyses to the primary and secondary analyses including all patients.

STATISTICAL ANALYSES: Differences in continuous variables between two groups will be tested using Student's t-test, and correlations between continuous variables will be assessed using Pearson's correlation test. The association between two dichotomous variables will be analyzed using Pearson's chi-square test. Temporal changes in plasma ionized calcium concentration across the entire study population will be analyzed using one-way analysis of variance (ANOVA). Post hoc comparisons will be performed using Dunnett's test, in which perioperative plasma ionized calcium concentrations will be compared with pre-CPB values. The association between plasma ionized calcium and UDPB class will be assessed with regression models. In addition to the primary, secondary and sensitivity analyses, corresponding multivariable analyses will be performed adjusted for clinical risk factors for bleeding. The clinical risk factors included in the model will be those previously identified by the research group among cardiac surgery patients at Meilahti Hospital. Multicollinearity among explanatory variables in the multivariable models will be considered present if the variance inflation factor (VIF) exceeds 5. In the presence of multicollinearity, the variable considered more clinically relevant for the model will be prioritized, and secondarily, the variable showing the stronger univariable association with the outcome will be selected. Otherwise, all predefined explanatory variables will be included in the multivariable model regardless of their statistical significance in univariable analyses. If needed, the five-grade UDPB will be modified to meet the assumption for proportional odds in ordinal regression models. Linearity will be tested. If needed, non-linear modeling will be used. The extent of missing data is not known at the time of writing the study protocol. The need for imputation of missing data and the specific imputation methodology will be evaluated after the study dataset has been obtained. Results will be presented as means and standard deviations, frequencies and proportions, or odds ratios with 95% confidence intervals (CI). A two-sided p-value < 0.05 will be considered statistically significant.

Typ studie

Pozorovací

Zápis (Odhadovaný)

4300

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Eero Juhani Pesonen, MD, PhD, docent
  • Telefonní číslo: +358-40-5880781
  • E-mail: eero.pesonen@hus.fi

Studijní místa

      • Helsinki, Finsko, 00029 HUS
        • Helsinki University Hospital, Meilahti Hospital
        • Kontakt:
          • Eero Pesonen, MD, PhD, docent
          • Telefonní číslo: +358-40-5880781
          • E-mail: eero.pesonen@hus.fi
        • Vrchní vyšetřovatel:
          • Eero Pesonen, MD, PhD, docent
        • Dílčí vyšetřovatel:
          • Minna Ilmakunnas, MD, PhD, docent
        • Dílčí vyšetřovatel:
          • Peter Raivio, MD, PhD, docent
        • Dílčí vyšetřovatel:
          • Erika Wilkman, MD, PhD, docent
        • Dílčí vyšetřovatel:
          • Liisa Petäjä, MD, PhD
        • Dílčí vyšetřovatel:
          • Lotta Joenpolvi, medical student

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

All adult (age 18-100 years) patients who underwent open-heart surgery with cardiopulmonary bypass (surgery with a main procedure code in the NCSP classification F category, "Heart and Great Vessels of the Thorax", performed on extracorporeal perfusion, procedure code FXA00) in Helsinki University Hospital between January 2021 and March 2026.

Exclusion Criteria: Organ transplants (procedure code FQ), hemophilia, von Willebrand disease, or platelet function disorders (ICD-10 codes D65-D69) and essential thrombocythemia (ICD-10 code D75.2).

Popis

Inclusion Criteria:

  • age 18-100 years
  • open-heart surgery with cardiopulmonary bypass (surgery with a main procedure code in the NCSP classification F category, "Heart and Great Vessels of the Thorax", performed on extracorporeal perfusion, procedure code FXA00)
  • between January 2021 and March 2026

Exclusion Criteria:

  • organ transplants (procedure code FQ)
  • hemophilia, von Willebrand disease, or platelet function disorders (ICD-10 codes D65-D69)
  • essential thrombocythemia (ICD-10 code D75.2)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
adult patients undergoing cardiac surgery with cardiopulmonary bypass
All adult (age 18-100 years) patients who underwent open-heart surgery with cardiopulmonary bypass (surgery with a main procedure code in the NCSP classification F category, "Heart and Great Vessels of the Thorax", performed on extracorporeal perfusion, procedure code FXA00) in Helsinki University Hospital between January 2021 and March 2026. Exclusion Criteria: Organ transplants (procedure code FQ), hemophilia, von Willebrand disease, or platelet function disorders (ICD-10 codes D65-D69) and essential thrombocythemia (ICD-10 code D75.2).

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Time-weighted plasma ionized calcium concentration during the post-CPB phase in OR for the primary and secondary analyses.
Časové okno: The time interval between the cessation of CPB and the exit from OR.
Time-weighted plasma ionized calcium concentration as a continuous parameter during the post-CPB phase in OR (i.e., the time interval between the cessation of CPB and the exit from OR) in the patients who did not receive blood products during the post-CPB phase.
The time interval between the cessation of CPB and the exit from OR.
Dichotomized UDPB (Universal Definition of Perioperative Bleeding).
Časové okno: From the cessation of CPB till the end of the first 24 postoperative hours in ICU or till the exit from ICU, whichever occurred first.
UDPB (Universal Definition of Perioperative Bleeding) as a measure of perioperative bleeding and dichotomized into UDPB 0-2 vs. UDPB 3-4 in the patients who did not receive blood products during the post-CPB phase.
From the cessation of CPB till the end of the first 24 postoperative hours in ICU or till the exit from ICU, whichever occurred first.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Original five-grade UDPB (Universal Definition of Perioperative Bleeding).
Časové okno: From the cessation of CPB till the end of the first 24 postoperative hours in ICU or till the exit from ICU, whichever occurred first.
Five-grade UDPB (Universal Definition of Perioperative Bleeding) as a measure of perioperative bleeding in the patients who did not receive blood products during the post-CPB phase.
From the cessation of CPB till the end of the first 24 postoperative hours in ICU or till the exit from ICU, whichever occurred first.

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Time-weighted plasma ionized calcium concentration during the post-CPB phase in OR for both sensitivity analyses of all patients.
Časové okno: The time interval between the cessation of CPB and the exit from OR.
Time-weighted plasma ionized calcium concentration as a continuous parameter during the post-CPB phase in OR (i.e., the time interval between the cessation of CPB and the exit from OR) in all patients.
The time interval between the cessation of CPB and the exit from OR.
Sensitivity analysis for dichotomized UDPB (Universal Definition of Perioperative Bleeding) in all patients.
Časové okno: From the cessation of CPB till the end of the first 24 postoperative hours in ICU or till the exit from ICU, whichever occurred first.
UDPB (Universal Definition of Perioperative Bleeding) as a measure of perioperative bleeding and dichotomized into UDPB 0-2 vs. UDPB 3-4 in all patients.
From the cessation of CPB till the end of the first 24 postoperative hours in ICU or till the exit from ICU, whichever occurred first.
Sensitivity analysis for original five-grade UDPB (Universal Definition of Perioperative Bleeding) in all patients.
Časové okno: From the cessation of CPB till the end of the first 24 postoperative hours in ICU or till the exit from ICU, whichever occurred first.
Five-grade UDPB (Universal Definition of Perioperative Bleeding) as a measure of perioperative bleeding in all patients.
From the cessation of CPB till the end of the first 24 postoperative hours in ICU or till the exit from ICU, whichever occurred first.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. června 2026

Primární dokončení (Odhadovaný)

31. prosince 2026

Dokončení studie (Odhadovaný)

31. prosince 2029

Termíny zápisu do studia

První předloženo

28. května 2026

První předloženo, které splnilo kritéria kontroly kvality

3. června 2026

První zveřejněno (Aktuální)

8. června 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

8. června 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

3. června 2026

Naposledy ověřeno

1. června 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

EU and national legislation restrict the distribution of personal health data. No data is available outside the authorized use within the HUS Acamedic or Findata platforms.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit